Search

Search Results

• SYSTEMIC MASTOCYTOSIS: MOLECULAR LANDSCAPE AND IMPLICATIONS FOR TREATMENT

  Cecilia Monaldi, Sara De Santis, Manuela Mancini, Samantha Bruno, Michele Cavo, Simona Soverini

  e2021046

  2021-06-28

  https://doi.org/10.4084/MJHID.2021.046

  1423

  PDF: 745

  HTML: 307

• THE JAK2V617F POINT MUTATION INCREASES THE OSTEOCLAST FORMING ABILITY OF MONOCYTES IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS AND MAKES THEIR OSTEOCLASTS MORE SUSCEPTIBLE TO JAK2 INHIBITION

  Emmanouil Spanoudakis, Menelaos Papoutselis, Ioanna Bazntiara, Eleftheria Lamprianidou, Xrisa Kordella, Constantinos Tilkeridis, Constantinos Tsatalas, Ioannis Kotsianidis

  e2018058

  2018-10-27

  https://doi.org/10.4084/mjhid.2018.058

  1371

  PDF: 844

  HTML: 185

• IS ALLOGENEIC TRANPLANTATION AN OPTION IN PATIENTS AFFECTED BY CONCURRENT MYELOFIBROSIS AND CHRONIC MYELOID LEUKEMIA (CML)?

  Federica Sorà, Patrizia Chiusolo, Francesco autore, Sabrina Giammarco, luca laurenti, elisabetta metafuni, idanna innocenti, eugenio galli, andrea bacigalupo, simona sica

  e2021062

  2021-10-29

  https://doi.org/10.4084/MJHID.2021.062

  1250

  PDF: 476

  HTML: 164

• Can Polycythemia Vera evolve from Acute Myeloid Leukemia? A Case Report Showing a Simultaneous Minor JAK2 V617F Mutated Clone, De novo polycythemia vera following AML remission

  Beatrice Borsellino, Arianna Savi, Maria Rosaria Pascale, Elisa Meddi, Antonio Cristiano, TIZIANA OTTONE, Maria Cristina Rapanotti, Mariadomenica Divona, SERENA TRAVAGLINI, Enrico Attardi, Elisa Buzzatti, Francesco Buccisano, Maria Teresa Voso

  e2022058

  2022-06-29

  https://doi.org/10.4084/MJHID.2022.058

  1695

  PDF: 787

  HTML: 264

• Lung Clear “Sugar” Cell Tumor and Jak V617f Positive Essential Thrombocythemia: A simple Co?nc?dence?

  Volkan Yazak, Gokhan Sargin, Irfan Yavasoglu, Gurhan Kadikoylu, Canten Tataroglu, Gokay Bozkurt, Zahit Bolaman

  e2013021

  2013-04-10

  https://doi.org/10.4084/mjhid.2013.021

  1294

  PDF: 719

  HTML: 2632

• UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)

  José Luis Piñana, Estela Giménez, Lourdes Vázquez, María Ángeles Marcos, Manuel Guerreiro, Rafael Duarte, Ariadna Pérez, Carlos de Miguel, Ildefonso Espigado, Marta González-Vicent, María Suarez-Lledó, Irene García-Cadenas, Rodrigo Martino, Angel Cedillo, Monserrat Rovira, Rafael de la Cámara, David Navarro, Carlos Solano

  e2024065

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.065

  4014

  Suppl. Files: 1143

  PDF: 1089

  Html: 181

• THE Co-Occurrence of Jak2/Calr-Positive Myeloproliferative Disorder and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib. Dual Myeloid Disorder Treated with Two Drug Association

  Katia Paciaroni, Selenia Campagna, Nicoletta Villiva', Enrico Maffini, Francesca Celesti, Attilio Tordi, Mariangela Lombardi, Giulia Dragonetti, Tommaso Caravita di Toritto

  e2025023

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.023

  1087

  PDF: 1172

  HTML: 98

• DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA

  Sabina Chiaretti, Gina Zini, Renato Bassan

  e2014073

  2014-10-24

  https://doi.org/10.4084/mjhid.2014.073

  9169

  PDF: 6109

  HTML: 87969

  Fig.1b: 192

  Fig.1c: 199

  Fig.2a: 185

  Fig.2b: 183

  Fig.4: 196

  Fig.2c: 191

  Fig.3: 189

  Tab.1: 240

  Tab.2: 215

  Tab.3: 197

  Tab.4: 231

  Fig1a: 196

• EBV-RELATED LYMPHOPROLIFERATIVE DISEASES: A REVIEW IN LIGHT OF NEW CLASSIFICATIONS EBV-RELATED LYMPHOPROLIFERATIVE DISEASES

  Pietro Tralongo, Arianna Bakacs, Luigi Maria Larocca

  e2024042

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.042

  4413

  PDF: 1726

  HTML: 1046

• HYDROXYCARBAMINE: FROM AN OLD DRUG USED IN MALIGNANT HEMOPATHIES TO A CURRENT STANDARD IN SICKLE CELL DISEASE

  Giovanna Cannas, Solene Poutrel, Xavier Thomas

  e2017015

  2017-02-15

  https://doi.org/10.4084/mjhid.2017.015

  3970

  PDF: 1183

  HTML: 1658

• Ph-negative chronic myeloproliferative neoplasm (primary myelofibrosis)– as one of the reasons of the Budd-Chiari syndrome.

  Maria Dmitrievna Sanatko

  e2012047

  2012-06-30

  https://doi.org/10.4084/mjhid.2012.047

  2396

  PDF: 881

  HTML: 687

  Untitled: 161

• NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL

  Dimitar Efremov, Adrian Wiestner, Luca Laurenti

  e2012067

  2012-10-09

  https://doi.org/10.4084/mjhid.2012.067

  2564

  PDF: 853

  HTML: 8902

  Efremov 1: 237

  Efremov 2: 202

• CHRONIC MYELOPROLIFERATIVE NEOPLASMS: A COLLABORATIVE APPROACH

  Lisa Pieri, Paola Guglielmelli, Alessandro Maria Vannucchi

  e2010017

  2010-06-18

  https://doi.org/10.4084/mjhid.2010.017

  1704

  PDF: 747

  HTML: 2347